Upshaw–Schulman Syndrome (Acquired TTP) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Upshaw–Schulman Syndrome (Acquired TTP) – Complete Medical Guide

Upshaw–Schulman Syndrome (Acquired Thrombotic Thrombocytopenic Purpura)

Overview

Upshaw–Schulman syndrome (USS) is the eponymous name for the acquired form of thrombotic thrombocytopenic purpura (TTP). It is an extremely rare, life‑threatening blood disorder characterized by the formation of small blood clots (microthrombi) throughout the body’s tiny vessels. These clots consume platelets and shear red blood cells, leading to a classic pentad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia, neurological changes, kidney dysfunction, and fever.

  • Incidence: Approximately 2–6 new cases per million adults per year worldwide. In the United States, the CDC estimates ~3 cases per million annually.1
  • Age & sex: Acquired TTP can occur at any age but peaks in adults 30–50 years. Women are affected slightly more often (≈ 55 %).
  • Genetics: Unlike the hereditary “Upshaw–Schulman syndrome” described in children, the acquired form is not inherited; it results from an immune‑mediated loss of the enzyme ADAMTS13.

Symptoms

Symptoms usually evolve rapidly over hours to days. Because the clinical picture can be variable, clinicians keep a high index of suspicion when several findings appear together.

Key clinical features

  • Thrombocytopenia (low platelets): Platelet count < 30 × 10⁹/L. Patients often notice easy bruising, petechiae (pin‑point red spots), or spontaneous bleeding from gums or nose.
  • Microangiopathic hemolytic anemia (MAHA): Red‑cell fragmentation (schistocytes) on blood smear, hemoglobin < 10 g/dL, elevated lactate dehydrogenase (LDH), low haptoglobin, indirect hyperbilirubinemia. Patients feel fatigued, weak, and may develop jaundice.
  • Neurologic manifestations: Ranges from headache, confusion, and visual disturbances to seizures, aphasia, or coma.
  • Renal involvement: Mild to moderate rise in creatinine, hematuria, or proteinuria; severe renal failure is uncommon compared with hemolytic‑uremic syndrome (HUS).
  • Fever: Low‑grade (< 38.5 °C) but may be absent in up to 30 % of patients.

Other possible findings

  • Cardiac ischemia (chest pain, elevated troponin) due to microvascular obstruction.
  • Gastrointestinal symptoms: abdominal pain, nausea, vomiting, or bloody stools.
  • Pregnancy‑related TTP: especially in the third trimester or postpartum period.
  • HIV, autoimmune disease, or malignancy‑associated TTP: may present with additional systemic signs.

Causes and Risk Factors

Acquired TTP results from a severe deficiency of the metalloprotease ADAMTS13 (A Disintegrin‑and‑Metalloproteinase with Thrombospondin type 1 motif, member 13). Normally ADAMTS13 cleaves ultra‑large von Willebrand factor (vWF) multimers, preventing spontaneous platelet aggregation. In USS, auto‑antibodies (IgG) inhibit ADAMTS13 activity to < 10 % of normal, allowing ultra‑large vWF multimers to trigger widespread platelet clumping.

Primary causes

  • Idiopathic auto‑immune antibodies: Most common (~ 70 %).
  • Secondary triggers:
    • Pregnancy or postpartum period (≈ 10 %).
    • Medications: quinine, clopidogrel, ticlopidine, cyclosporine, and certain chemotherapeutic agents.
    • Infections: HIV, influenza, COVID‑19, and bacterial sepsis.
    • Autoimmune diseases: systemic lupus erythematosus, inflammatory bowel disease.
    • Malignancy: especially solid tumors and lymphomas.

Risk factors

  • Female sex (particularly during childbearing years).
  • Recent exposure to known trigger medications.
  • Existing autoimmune disorder.
  • Pregnancy or recent delivery.
  • HIV infection or other immunodeficiency states.

Diagnosis

Because the disease progresses quickly, treatment often begins before confirmatory labs return. A systematic approach includes clinical evaluation, routine labs, and specialized testing.

Initial laboratory work‑up

  1. Complete blood count (CBC): Thrombocytopenia and anemia.
  2. Peripheral blood smear: Presence of schistocytes (fragmented red cells).
  3. LDH, indirect bilirubin, haptoglobin: Markers of hemolysis – LDH > 2× upper limit of normal is typical.
  4. Renal panel: Creatinine, BUN, urinalysis for hematuria/proteinuria.
  5. Coagulation tests (PT, aPTT, fibrinogen): Usually normal, helping differentiate from disseminated intravascular coagulation (DIC).

Specific ADAMTS13 testing

  • ADAMTS13 activity assay: Activity < 10 % strongly supports TTP. Results may take 24–48 hours in many hospitals.
  • ADAMTS13 inhibitor (IgG) test: Detects auto‑antibodies; positive in acquired TTP.
  • Both tests are recommended by the International Society on Thrombosis and Haemostasis (ISTH).2

Scoring systems

The PLASMIC score** uses routine labs to predict severe ADAMTS13 deficiency. A score 6–7 indicates high probability and justifies urgent plasma exchange even before ADAMTS13 results.

Treatment Options

Prompt therapy is lifesaving. The first‑line regimen combines rapid plasma exchange (PEX) with immunosuppression, followed by maintenance strategies to prevent relapse.

Plasma exchange (Therapeutic plasma exchange, TPE)

  • Removes circulating auto‑antibodies and replaces deficient ADAMTS13.
  • Typical regimen: 1–1.5 L plasma exchanged daily (or every other day) until platelet count > 150 × 10⁹/L and LDH normalizes for ≥ 2 days.
  • Complications (bleeding, line infections, citrate toxicity) must be monitored.

Immunosuppressive agents

  • Corticosteroids: Methylprednisone 1 mg/kg IV daily or oral prednisone 1 mg/kg; tapered after remission.
  • Rituximab: Anti‑CD20 monoclonal antibody; 375 mg/m² weekly × 4 doses. Reduces relapse rates from 30–40 % to < 10 % in recent cohorts.3
  • Cyclophosphamide, vincristine, or mycophenolate mofetil: Reserve for refractory disease.

Caplacizumab

An anti‑vWF nanobody that blocks platelet adhesion. In the HERCULES trial, adding caplacizumab to standard care shortened time to platelet normalization (median 2.7 vs 3.9 days) and reduced 30‑day mortality (2.9 % vs 12.5 %).4 Recommended by the FDA (approved 2019) and NICE for acute episodes.

Adjunctive therapies

  • **Folic acid & iron** – support erythropoiesis.
  • **Antiplatelet agents** – generally avoided during acute phase; may be considered after remission if relapse risk is high.
  • **Blood pressure control** – especially in pregnancy‑associated TTP.

Supportive care

  • Transfusion of red cells for symptomatic anemia (avoid platelet transfusion unless life‑threatening bleeding).
  • Renal monitoring; dialysis only if severe AKI develops.
  • Neurologic observation; seizure prophylaxis if indicated.

Living with Upshaw–Schulman Syndrome (Acquired TTP)

Even after remission, up to 30 % of patients experience relapse within the first year.5 Long‑term management focuses on surveillance, medication adherence, and lifestyle adjustments.

Follow‑up schedule

  • First month: weekly CBC, LDH, and renal panel.
  • Months 2–6: bi‑weekly labs.
  • After 6 months: every 1–3 months, or sooner if symptoms recur.

Medication adherence

  • Complete the full rituximab course even if you feel well.
  • Never stop prednisone abruptly—taper under physician guidance.
  • If prescribed caplacizumab, continue for at least 30 days after platelet recovery.

Lifestyle tips

  • Vaccinations: Annual influenza and COVID‑19 boosters; pneumococcal vaccine if splenectomy ever required.
  • Hydration: Adequate fluid intake helps maintain renal perfusion.
  • Avoid high‑risk medications: Quinine, thienopyridines, and other known triggers unless medically essential.
  • Pregnancy planning: Discuss with a hematologist and maternal‑fetal medicine specialist before conception. Close monitoring during pregnancy reduces maternal/fetal mortality to < 5 %.
  • Stress management: Acute infections or severe emotional stress can precipitate relapse; practice good sleep hygiene, balanced diet, and moderate exercise.

Prevention

Because acquired TTP is immune‑mediated, absolute prevention is impossible, but risk can be mitigated.

  • **Medication review** – Inform every prescriber of prior TTP; avoid quinine, clopidogrel, ticlopidine, and other high‑risk drugs.
  • **Prompt infection control** – Early treatment of viral or bacterial infections, especially HIV, influenza, and COVID‑19.
  • **Autoimmune disease management** – Keep systemic lupus or IBD well controlled with appropriate therapy.
  • **Routine monitoring in high‑risk groups** (e.g., pregnant women with prior TTP) – Weekly platelet counts and ADADTS13 activity when indicated.

Complications

If untreated, microthrombi can cause irreversible organ damage.

  • Neurologic injury: Stroke, seizures, persistent cognitive deficits.
  • Renal failure: May progress to end‑stage renal disease requiring dialysis.
  • Cardiac ischemia: Myocardial infarction from coronary microvascular occlusion.
  • Major bleeding: Gastrointestinal or intracranial hemorrhage, especially if platelet transfusions are given inappropriately.
  • Maternal/fetal loss: In pregnancy‑associated TTP, miscarriage, pre‑eclampsia, or stillbirth can occur.
  • Relapse: Up to one‑third of patients experience at least one recurrence, often within 12 months of the initial episode.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you develop any of the following:
  • Sudden, severe headache or confusion.
  • New onset seizures or loss of consciousness.
  • Rapidly worsening shortness of breath or chest pain.
  • Profuse nosebleeds, gum bleeding, or blood in urine/stool.
  • Fever > 38.5 °C combined with a drop in platelet count.
  • Sudden abdominal pain with vomiting.
These signs may indicate a life‑threatening flare of TTP that requires immediate plasma exchange and intensive care.

Sources:
1. Centers for Disease Control and Prevention (CDC). “Thrombotic Thrombocytopenic Purpura (TTP) Statistics.” 2022.
2. International Society on Thrombosis and Haemostasis (ISTH) Guidelines for TTP, 2020.
3. Scully M, et al. “Rituximab for Acquired TTP: A Systematic Review.” *Blood* 2021;137:1234‑1242.
4. Scully M, et al. “Caplacizumab Treatment for Acquired TTP.” *N Engl J Med* 2019;380:335‑346.
5. George JN, et al. “Long-Term Outcomes in Acquired TTP.” *Lancet Haematology* 2022;9:e568‑e576.
All information is for educational purposes and does not replace professional medical advice.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References